Trial Profile
A Phase IV Confirmatory Clinical Trial of Galafold (Migalastat) in Patients with Fabry Disease
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2018
Price :
$35
*
At a glance
- Drugs Migalastat (Primary)
- Indications Fabry's disease
- Focus Therapeutic Use
- Sponsors Amicus Therapeutics
- 10 Aug 2018 According to an Amicus Therapeutics media release, as a condition of accelerated approval, the company will study Galafold in this confirmatory phase 4 study.
- 17 Sep 2015 New trial record